SCHEMBL20338306

SCHEMBL20338306

CCOC(=O)C1CC(C(F)(F)F)=NNC1=O

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.60
LMNA P02545 1/20 0.54
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 4/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPK1 P28482 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.33
PLAT P00750 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19463937 0.81 RAB9A (0.63) RAB9ALMNAALDH1A1KDM4EMAPT
SCHEMBL23609124 0.78 RAB9A (0.56) RAB9ALMNAALDH1A1KDM4EMAPT
SCHEMBL19463838 0.76 RAB9A (0.57) RAB9ALMNAALDH1A1KDM4EMAPT
SCHEMBL6014875 0.75 RAB9A (1.00) RAB9ALMNAALDH1A1KDM4EMAPT
SCHEMBL28802880 0.70 LMNA (1.00) RAB9ALMNAALDH1A1MAPTMEN1
SCHEMBL7277682 0.70 LMNA (0.78) RAB9ALMNAALDH1A1KDM4EMAPT
SCHEMBL1322979 0.69 RAB9A (0.49) RAB9ALMNAALDH1A1KDM4EMAPT
SCHEMBL25439588 0.69 RAB9A (0.49) RAB9ALMNAALDH1A1KDM4EMAPT
Benzene SCHEMBL27598160 0.69 RAB9A (0.55) RAB9ALMNAALDH1A1KDM4EMAPT
SCHEMBL10405813 0.68 RAB9A (0.48) RAB9ALMNAALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LTD (HK) 2026-04-09 US disclosed
US-12458642-B2 Metalloenzyme inhibitor compounds CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2025-11-04 US disclosed
EP-4311577-A2 METALLOENZYME INHIBITOR COMPOUNDS Ji Xing Pharmaceuticals Hong Kong Limited (HK) 2024-01-31 EP disclosed
EP-3562487-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2023-11-29 EP disclosed
EP-3562487-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2023-11-29 EP disclosed
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) 2021-10-21 US disclosed
US-11040034-B2 Metalloenzyme inhibitor compounds PHASEBIO PHARMACEUTICALS, INC. (US) 2021-06-22 US disclosed
US-11040034-B2 Metalloenzyme inhibitor compounds PHASEBIO PHARMACEUTICALS, INC. (US) 2021-06-22 US disclosed
CN-110691598-A Metalloenzyme inhibitor compounds 赛列尼蒂治疗(百慕大)有限公司 2020-01-14 CN disclosed
EP-3562487-A2 METALLOENZYME INHIBITOR COMPOUNDS Selenity Therapeutics (Bermuda), Ltd. (BM) 2019-11-06 EP disclosed
US-20190008861-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2019-01-10 US disclosed
US-10085984-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-10-02 US disclosed
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed
WO-2018125800-A2 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-07-05 WO disclosed
WO-2018125800-A2 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458642-B2 Metalloenzyme inhibitor compounds CYP11B2, CYP11B1, HSD11B2 RAB9A 2914/4885LMNA 3671/4885ALDH1A1 232/4885
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH RAB9A 2443/4885LMNA 4166/4885ALDH1A1 457/4885
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CPN1, TPP1, DPP4 RAB9A 1863/4885LMNA 3168/4885ALDH1A1 189/4885
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH RAB9A 2443/4885LMNA 4166/4885ALDH1A1 457/4885
US-11040034-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH RAB9A 2443/4885LMNA 4166/4885ALDH1A1 457/4885
US-20190008861-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH RAB9A 2443/4885LMNA 4166/4885ALDH1A1 457/4885
US-10085984-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH RAB9A 2443/4885LMNA 4166/4885ALDH1A1 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.